We are live on ! Find out more
Jacobs Levy Equity Management

Jacobs Levy Equity Management Portfolio holdings

AUM $23.8B
1-Year Est. Return 25.4%
This Fund
S&P 500
This Quarter Est. Return
+6.28%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$5.18B
AUM Growth
-$419M
Cap. Flow
-$653M
Cap. Flow %
-12.61%
Top 10 Hldgs %
12.12%
Holding
1,157
New
156
Increased
241
Reduced
474
Closed
210

Sector Composition

Rank Sector Weight
1 Technology 18.78%
2 Financials 17.57%
3 Healthcare 14.1%
4 Industrials 10.7%
5 Consumer Discretionary 9.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IVAC
901
DELISTED
Intevac Inc
IVAC
$108K ﹤0.01%
12,619
-16,500
-57% -$104K
DXYN
902
DELISTED
Dixie Group Inc
DXYN
$108K ﹤0.01%
30,080
-12,840
-30% -$50K
GNCA
903
DELISTED
Genocea Biosciences, Inc.
GNCA
$107K ﹤0.01%
3,260
-2,852
-47% -$93.9K
SHLO
904
DELISTED
Shiloh Industries Inc
SHLO
$106K ﹤0.01%
+15,400
New +$108K
SCX
905
DELISTED
The L.S. Starrett Company
SCX
$105K ﹤0.01%
11,270
-9,073
-45% -$88.4K
MXPT
906
DELISTED
MaxPoint Interactive, Inc.
MXPT
$105K ﹤0.01%
17,467
-3,500
-17% -$28.9K
CDXS icon
907
Codexis
CDXS
$135M
$104K ﹤0.01%
22,500
-10,829
-32% -$50.8K
AMRC icon
908
Ameresco
AMRC
$1.15B
$98K ﹤0.01%
17,900
-3,600
-17% -$20K
HWCC
909
DELISTED
Houston Wire & Cable Company
HWCC
$95K ﹤0.01%
14,624
-7,290
-33% -$43.9K
LRMR icon
910
Larimar Therapeutics
LRMR
$416M
$93K ﹤0.01%
+2,433
New +$98.7K
SPRT
911
DELISTED
support.com, Inc.
SPRT
$92K ﹤0.01%
35,542
-42,100
-54% -$97.7K
CBK
912
DELISTED
Christopher & Banks Corporation
CBK
$92K ﹤0.01%
39,230
+21,600
+123% +$37K
ULBI icon
913
Ultralife
ULBI
$88.3M
$90K ﹤0.01%
18,151
-12,400
-41% -$55.7K
ENPH icon
914
Enphase Energy
ENPH
$4.84B
$88K ﹤0.01%
86,894
+33,500
+63% +$38.4K
PRGX
915
DELISTED
PRGX Global, Inc.
PRGX
$86K ﹤0.01%
14,638
-25,420
-63% -$131K
EGAN icon
916
eGain
EGAN
$176M
$84K ﹤0.01%
39,866
+18,461
+86% +$47K
UTI icon
917
Universal Technical Institute
UTI
$2.08B
$84K ﹤0.01%
+28,700
New +$66.3K
SRGA
918
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$83K ﹤0.01%
847
SNMX
919
DELISTED
Senomyx, Inc.
SNMX
$83K ﹤0.01%
86,882
IMDZ
920
DELISTED
Immune Design Corp.
IMDZ
$82K ﹤0.01%
+14,943
New +$106K
APPS icon
921
Digital Turbine
APPS
$1.02B
$80K ﹤0.01%
117,372
-25,900
-18% -$20.2K
IMI
922
DELISTED
Intermolecular, Inc.
IMI
$80K ﹤0.01%
84,345
OESX icon
923
Orion Energy Systems
OESX
$41.1M
$79K ﹤0.01%
3,644
-1,533
-30% -$26.6K
TACT icon
924
Transact Technologies
TACT
$51.7M
$77K ﹤0.01%
+11,733
New +$78.9K
CALA
925
DELISTED
Calithera Biosciences, Inc
CALA
$72K ﹤0.01%
1,103
+275
+33% +$17.2K

Similar funds

Jacobs Levy Equity Management's Q4 2016 Portfolio in Review

As of Q4 2016, Jacobs Levy Equity Management held 1,157 positions worth $5.18B, down 7.5% from $5.6B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Jacobs Levy Equity Management withdrew a net $653M in Q4 2016, closing 210 positions and reducing 474 holdings. Its most notable exit was Nike, an estimated $39.1M position sold in full.

By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Jacobs Levy Equity Management opened a new position in Express Scripts Holding Company worth $34.6M.

  • Jacobs Levy Equity Management's largest Q4 2016 buy was Express Scripts Holding Company: 502,999 shares worth $34.6M.
  • Jacobs Levy Equity Management added most to State Street SPDR S&P MIDCAP 400 ETF Trust in Q4 2016, an estimated $34.6M increase.
  • Jacobs Levy Equity Management's biggest Q4 2016 reduction was Alphabet (Google) Class C, cutting an estimated $34.2M.
  • Jacobs Levy Equity Management fully exited Nike in Q4 2016, selling an estimated $39.1M.
  • Jacobs Levy Equity Management's ten largest holdings make up 12% of its $5.18B portfolio in Q4 2016.
  • Jacobs Levy Equity Management opened 156 new positions and closed 210 in Q4 2016.
  • Jacobs Levy Equity Management's portfolio value fell 7.5% quarter-over-quarter to $5.18B.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2016, filed 14 Feb 2017.